ATHA · Athira Pharma, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $11.26M | - | $2.83M | $3.66M | $4.30M | - | $17.92M | $22.15M | $21.24M | - |
| SG&A | $6.88M | - | $4.05M | $3.63M | $5.23M | - | $7.57M | $5.87M | $6.45M | - |
| Total Operating Expenses | $17.21M | - | $6.87M | $7.29M | $9.54M | - | $29.62M | $28.03M | $27.69M | - |
| D&A | $231.0K | - | $200.0K | $200.0K | $243.0K | - | $243.0K | $242.0K | $242.0K | - |
| Operating Income | ($17.21M) | - | ($6.87M) | ($7.29M) | ($9.54M) | - | ($29.62M) | ($28.03M) | ($27.69M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($32.95M) | - | ($6.61M) | ($6.97M) | ($9.14M) | - | ($28.74M) | ($26.86M) | ($26.34M) | - |
| EPS - Basic | ($1.73) | - | ($1.68) | ($0.18) | ($0.23) | - | ($0.75) | ($0.70) | ($0.69) | - |
| EPS - Diluted | ($1.73) | - | ($1.68) | ($0.18) | ($0.23) | - | ($0.75) | ($0.70) | ($0.69) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $32.83M | $69.28M | $20.87M | $19.89M | $26.42M | $48.44M | $68.86M | $73.83M | $77.82M | $90.58M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.76M | $4.59M | $266.0K | $171.0K | $867.0K | $319.0K | $388.0K | $475.0K | $681.0K | $129.0K |
| Current Assets | $69.20M | $89.46M | $27.02M | $32.22M | $39.85M | $54.84M | $82.00M | $106.70M | $128.64M | $154.73M |
| Total Assets | $71.59M | $92.15M | $30.03M | $35.55M | $43.51M | $58.78M | $86.25M | $111.25M | $133.46M | $160.25M |
| Current Liabilities | $6.67M | $47.50M | $2.79M | $2.98M | $5.49M | $13.13M | $27.75M | $26.90M | $25.60M | $28.84M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $22.29M | $64.36M | $3.25M | $3.56M | $6.18M | $13.94M | $28.66M | $27.92M | $26.72M | $30.06M |
| Stockholders' Equity | $49.30M | $27.79M | $26.79M | $31.99M | $37.33M | $44.84M | $57.58M | $83.33M | $106.74M | $130.19M |
| Retained Earnings | ($544.70M) | ($511.75M) | ($428.87M) | ($422.25M) | ($415.29M) | ($406.15M) | ($391.14M) | ($362.40M) | ($335.54M) | ($309.21M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($20.90M) | - | - | - | ($14.66M) | - | - | - | ($25.80M) | - |
| Investing Cash Flow | ($15.54M) | - | - | - | ($7.35M) | - | - | - | $13.04M | - |
| Financing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | $5.0K | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | ($25.81M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | 0.98 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -46.0% | - | -22.0% | -19.6% | -21.0% | - | -33.3% | -24.1% | -19.7% | - |
| Return on equity | -66.8% | - | -24.7% | -21.8% | -24.5% | - | -49.9% | -32.2% | -24.7% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 10.38 | 1.88 | 9.70 | 10.81 | 7.26 | 4.18 | 2.95 | 3.97 | 5.03 | 5.37 |
| Quick ratio | 10.38 | 1.88 | 9.70 | 10.81 | 7.26 | 4.18 | 2.95 | 3.97 | 5.03 | 5.37 |
| Cash ratio | 4.93 | 1.46 | 7.49 | 6.67 | 4.81 | 3.69 | 2.48 | 2.74 | 3.04 | 3.14 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.45 | 3.32 | 1.12 | 1.11 | 1.17 | 1.31 | 1.50 | 1.34 | 1.25 | 1.23 |
| Liabilities / Assets | 0.31 | 0.70 | 0.11 | 0.10 | 0.14 | 0.24 | 0.33 | 0.25 | 0.20 | 0.19 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -80.5% | - | 76.8% | 74.0% | 65.6% | - | 15.5% | 11.4% | 7.0% | - |
| Net income growth (YoY) | -260.4% | - | 77.0% | 74.1% | 65.3% | - | 12.8% | 9.3% | 5.3% | - |
| EPS growth (YoY) | -652.2% | - | -124.0% | 74.3% | 66.7% | - | 13.8% | -7.7% | 5.5% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | 2.4% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 32.1% | -38.0% | -53.5% | -61.6% | -65.0% | -65.6% | -62.8% | -54.9% | -49.4% | -44.6% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Athira Pharma against the 5 most active filers in the same SIC group.